Molbio Diagnostics is set for a significant stock market debut following a robust IPO subscription of 70 times. With a promising grey market premium suggesting a 19.3% rise over its issue price, investors are eagerly awaiting Monday’s listing on the NSE and BSE.
Source :- mint – markets Read More
